Abstract
Fibrinopeptide A (FPA) is of particular interest, because it is released whenever thrombin converts fibrinogen to fibrin. Human FPA is a 16 amino acid peptide with a molecular weight of 1540, and it is cleaved from the N-terminal part of the Aα-chain of fibrinogen. Since the fibrinogen molecule has a dimer structure, two identical FPA molecules are cleaved from each fibrinogen molecule1.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Marder VJ, Francis CW, Doolittle RF Fibrinogen, structure and physiology. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds), Haemostasis and thrombosis. Philadelphia: Lippincott, 1982; 145–63.
Nossel HL, Younger LR, Wilner GD, Procupez D, Canfield RE, Butler VP Radioimmunoassay of human fibrinopeptide A. Proc Natl Acad Sci USA 1971; 68: 2350–3.
Nossel HL, Yudelman I, Canfield RE, Butler VP, Spanondis K, Wilner GD, Qureshi GD Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43–53.
Bauer KA, Rosenberg RD The pathophysiology of the prethrombotic state in humans: Insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343–50.
Hirsh J Blood tests for the diagnosis of venous and arterial thrombosis. Blood 1981; 57: 1–8.
Joist JH Fibrinopeptide A in the diagnosis and treatment of deep venous thrombosis and pulmonary embolism. Clin Lab Med 1984; 4: 363–80.
Douglas IT, Blarney SL, Lowe GDO, Carter DC, Forbes CD Plasma beta-thromboglobulin, fibrinopeptide A and Bß 15–42 antigen in relation to postoperative DVT, malignancy and stanozolol treatment. Thromb Haemostas 1985; 53: 235–8.
Leeksma OC, Meijer-Huizinga F, Stoepman-van-Dalen EA, van Ginkel CJW, van Aken WG, van Mourik JA Fibrinopeptide A and the phosphate content of fibrinogen in venous thromboembolism and disseminated intravascular coagulation. Blood 1986; 67: 1460–7.
Nossel HL Radioimmunoassay of fibrinopeptides in relation to intravascular coagulation and thrombosis. N Engl J Med 1976; 295: 428–32.
Van Hulsteijn H, Briet E, Koch C, Hermans J, Bertina R Diagnostic value of fibrinopeptide A and beta-thromboglobulin in acute deep venous thrombosis and pulmonary embolism. Acta Med Scand 1982; 211: 323–30.
Yudelman IM, Nossel HL, Kaplan KL, Hirsh J Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. Blood 1978; 51: 1189–95.
Cronlund M, Hardin J, Burton J, Lee L, Haber E, Bloch KJ Fibrinopeptide A in plasma of normal subjects and patients with disseminated intravascular coagulation and systemic lupus erythematosus. J Clin Invest 1976; 58: 142–51.
Mombelli G, Monotti R, Haeberli A, Straub PW Relationship between fibrinopeptide A and fibrinogen/fibrin fragment E in thromboembolism, DIC and various non-thromboembolic diseases. Thromb Haemostas 1987; 58: 758–63.
Eisenberg PR, Lucore C, Kaufman L, Sobel BE, Jaffe AS, Rich S Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 1990; 82: 841–7.
Douglas JT, Lowe GDO, Forbes CD, Prentice CRM Plasma fibrinopeptide A and beta-thromboglobulin in patients with chest pain. Thromb Haemostas 1983; 50: 541–2.
Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS Fibrinopeptide A: a marker of acute coronary thrombosis. Circulation 1985; 71: 912–18.
Gallino A, Haeberli A, Baur HR, Straub PW Fibrin formation and platelet aggregation in patients with severe coronary artery disease: relationship with the degree of myocardial ischemia. Circulation 1985; 72: 27–30.
Gallino A, Haeberli A, Hess T, Mombelli G, Straub PW Fibrin formation and platelet aggregation in patients with acute myocardial infarction: effects of intravenous and subcutaneous low-dose heparin. Am Heart J 1986; 112: 285–90.
Gensini GF, Rostagno C, Abbate R, Favilla S, Mannucci PM, Neri Semeri GG Increased protein C and fibrinopeptide A concentration in patients with angina. Thromb Res 1988; 50: 517–25.
Irie T, Imaaizumi T, Matuguchi T, Koyanagi S, Kanaide H, Takeshita A, Nakamura M Increased fibrinopeptide A during anginal attacks in patients with variant angina. J Am Coll Cardiol 1989; 14: 589–94.
Mombelli G, Im Hof V, Haeberli A, Straub PW Effect of heparin on plasma fibrinopeptide A (fpA) in acute myocardial infarction. Circulation 1984; 69: 684–9.
Neri Semeri G, Gensini GF, Camovali M, Prisco D, Rogasi PG, Casolo GC, Fazi A, Abbate R Association between time of increased fibrinopeptide A levels in plasma and episodes of spontaneous angina: A controlled prospective study. Am Heart J 1987; 113: 672–8.
Nichols AB, Owen J, Kaplan KL, Sciacca RR, Cannon PJ, Nossel HL Fibrinopeptide A, platelet factor 4, and p-thromboglobulin levels in coronary heart disease. Blood 1982; 60: 650–4.
Theroux P, Latour JG, Leger-Gauthier C, De Lara J Fibrinopeptide A and platelet factor levels in unstable angina pectoris. Circulation 1987; 75: 156–62.
Van Hulsteijn H, Kolff J, Briet E, van der Laarse A, Bertina R Fibrinopeptide A and beta-thromboglobulin in patients with angina pectoris and acute myocardial infarction. Am Heart J 1984; 107: 39–45.
Landi G, Barbarotto R, Morabito A, D’Angelo A, Mannucci PM Prognostic significance of fibrinopeptide A in survivors of cerebral infarction. Stroke 1990; 21: 424–7.
Conway EM, Bauer KA, Barzegar S, Rosenberg RD. Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diseases. J Clin Invest 1987; 80: 1535–44.
Peuscher FW, van Aken WG, Flier OThN, Stoepman-van Dalen EA, Cremer-Goote TM, van Mourik JA Effect of anticoagulant treatment measured by fibrinopeptide A (fpA) in patients with venous thromboembolism. Thromb Res 1980; 18: 33–43.
Yudelman I, Greenberg J Factors affecting fibrinopeptide A levels in patients with venous thromboembolism during anticoagulant therapy. Blood 1982; 59: 787–92.
Auger MJ, Galloway MJ, Leinster SJ, McVerry BA, Mackie MJ Elevated fibrinopeptide A levels in patients with clinically localised breast carcinoma. Haemostasis 1987; 17: 336–9.
Edwards RL, Klaus M, Matthews E, McCullen C, Bona RD, Rickles FR Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med 1990; 89: 25–8.
Gugliotta L, Vigano S, D’Angelo A, Guarini A, Tura S, Mannucci PM High fibrinopeptide A (FPA) levels in acute non-lymphocytic leukemia are reduced by heparin administration. Thromb Haemostas 1984; 52: 301–4.
Mombelli G, Roux A, Haeberli A, Straub PW Comparison of 125I-fibrinogen kinetics and fibrinopeptide A in patients with disseminated neoplasias. Blood 1982; 60: 381–8.
Myers TJ, Rickles FR, Barb C, Cronlund M Fibrinopeptide A in acute leukemia: Relationship of activation of blood coagulation to disease activity. Blood 1981; 57: 518–25.
Peuscher FW, Cleton FJ, Armstrong L, Stoepman-van-Dalen EA, van Mourik JA, van Aken WG Significance of plasma fibrinopeptide A (fpA) in patients with malignancy. J Lab Clin Med 1980; 96: 5–14.
Douglas JT, Shah M, Lowe GDO, Belah JJF, Forbes CD, Prentice CRM. Plasma fibrinopeptide A and p-thromboglobulin in preeclampsia and pregnancy hypertension. Thromb Haemostas 1982; 47: 54–8.
Jones RL Fibrinopeptide A in diabetes mellitus. Relation to levels of blood glucose, fibrinogen disappearance and hemodynamic changes. Diabetes 1985; 34: 836–43.
Librenti MC, D’Angelo A, Micossi P, Garimberti B, Mannucci PM, Pozza G. p-thromboglobuIin and fibrinopeptide A in diabetes mellitus as markers of vascular damage. Acta Diabetol Lat 1985; 22: 39–45.
Rosove MH, Frank HJL, Harwig SSL Plasma p-thromboglobulin, platelet factor 4, fibrinopeptide A, and other hemostatic functions during improved, short-term glycemic control in diabetes mellitus. Diabetes Care 1984; 7: 174–9.
Roy MS, Podgar MJ, Rick ME Plasma fibrinopeptide A, p-thromboglobulin, and platelet factor 4 in diabetic retinopathy. Invest Opthalmol Vis Sci 1988; 29: 856–60.
Coccheri S, Mannucci PM, Palaretti G, Gervasoni W, Poggi M, Vigano S Significance of plasma fibrinopeptide A and high molecular weight fibrinogen in patients with liver cirrhosis. Br J Haematol 1982; 52: 503–9.
Marongiu F, Mameli G, Acca MR, Mulas G, Medda A, Tronci MB, Mamusa AM, Balestrieri A Fibrinopeptide A and BP 15-42 in liver cirrhosis. Haemostasis 1988; 18: 126–28.
Alkjaersig N, Fletcher AP, de Ziegler D, Steingold KA, Meldrum DR, Judd HL Blood coagulation in postmenopausal women given oestrogen treatment: comparison of transdermal and oral administration. J Lab Clin Med 1988; 111: 224–8.
Inauen W, Baumgartner HR, Haeberli A, Straub PW Excessive deposition of fibrin, platelets and platelet thrombi on vascular subendothelium during contraceptive drug treatment. Thromb Haemostas 1987; 57: 306–9.
Melis GB, Fruzzetti F, Paoletti AM, Carmassi F, Fioretti P Fibrinopeptide A plasma levels during low-estrogen oral contraceptive treatment. Contraception 1984; 30: 575–83.
Melis GB, Fruzzetti F, Ricci C, Carmassi F, Fioretti P Oral contraceptives and venous thromboembolic disease: the effect of the oestrogen dose. Maturitas, Suppl. 1988; 1: 131–9.
Hofmann V, Straub PW A radioimmunoassay technique for the rapid measurement of human fibrinopeptide A. Thromb Res 1977; 11: 171–81.
Kockum C, Frebelius S Rapid radioimmunoassay of human fibrinopeptide A — removal of cross-reacting fibrinogen with bentonite. Thromb Res 1980; 19: 589–98.
Soria J, Soria C, Ryckewaert JJ A solid phase immuno enzymological assay for the measurement of human fibrinopeptide A. Thromb Res 1980; 20: 425–35.
Alkjaersig N, Fletcher AP Catabolism and excretion of fibrinopeptide A. Blood 1982; 60: 148–56.
Gallino A, Haeberli A, Straub PW Fibrinopeptide A excretion in urine in patients with atherosclerotic artery disease. Thromb Res 1985; 38: 237–44.
Leeksma OC, Meijer-Huizinga F, Stoepman-van Dalen EA, van Aken WG, van Mourik JA Fibrinopeptide A in urine from patients with venous thromboembolism, disseminated intravascular coagulation and rheumatoid arthritis — Evidence for dephosphorylation and carboxy terminal degradation of the peptide by the kidney. Thromb Haemostas 1985; 54: 792–8.
Wilensky RL, Zeller JA, Wish M, Tulchinsky M Urinary fibrinopeptide A levels in ischemic heart disease. J Am Coll Cardiol 1989; 14: 597–603.
Kudryk B, Gidlund M, Rohoza A, Ahadi M, Coiffe D, Weitz JI Use of a synthetic homologue of human fibrinopeptide A for production of a monoclonal antibody specific for the free peptide. Blood 1989; 74: 1036–44.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Haeberli, A. (1992). Fibrinopeptide A (FPA). In: Jespersen, J., Bertina, R.M., Haverkate, F. (eds) ECAT Assay Procedures A Manual of Laboratory Techniques. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-2992-3_13
Download citation
DOI: https://doi.org/10.1007/978-94-011-2992-3_13
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-5330-3
Online ISBN: 978-94-011-2992-3
eBook Packages: Springer Book Archive